Mefenamic acid and diclofenac in the treatment of menorrhagia and dysmenorrhea in dysfunctional uterine bleeding: a randomized comparative study

Authors

  • Sahil Kumar Department of Pharmacology, Maulana Azad Medical College, (MAMC), Delhi, India http://orcid.org/0000-0003-0834-9330
  • Uma Tekur Department of Pharmacology, Maulana Azad Medical College, (MAMC), Delhi, India
  • Bhupinder Singh Department of Pharmacology, Maulana Azad Medical College, (MAMC), Delhi, India
  • Devender Kumar Department of Obstetrics & Gynecology, Lok Nayak Hospital, Delhi, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20183921

Keywords:

Abnormal uterine bleeding, Diclofenac, Dysmenorrhea, Mefenamic acid, Menorrhagia, NSAIDs

Abstract

Background: There is a perception that Mefenamic Acid should be the preferred NSAID for menorrhagia. However, there are insufficient evidences to prove this. Further RCTs are required to compare individual NSAIDs.

Purposes of the study were to assess and compare the efficacy of mefenamic acid and diclofenac in control of menorrhagia in patients with DUB, to assess and compare their analgesic effects in dysmenorrhea associated with DUB and to study their adverse effects.

Methods: Sixty-eight patients were randomized into either Mefenamic Acid (n=34) or Diclofenac (n=34) group. Efficacy variables (Pictorial Blood loss Assessment Chart quantification, Number of pads used, Number of days of menstrual bleeding, Visual Analog Scale score) and adverse effects were recorded over three menstrual cycles.

Results: The median reduction of menorrhagia with Mefenamic Acid was 43.39% (Range: 2.86% to 94.4%) and for Diclofenac was 57.5% (Range: 9.9% to 93.58%). The Diclofenac group showed a statistically significant decrease in median bleeding volume, median number of pads used and median number of days of bleeding compared to the Mefenamic Acid group (p<0.05, CI = 95%) but did not show a statistically significant decrease in median VAS score compared to the Mefenamic Acid group. Adverse effects with both groups were mild.

Conclusions: Mefenamic Acid and Diclofenac individually managed to significantly reduce excessive bleeding compared to baseline. Diclofenac fared better than Mefenamic Acid in terms of control of excessive menstrual bleeding. Both these agents were able to reduce the menstrual pain and on comparison, were found to be equi-efficacious.

References

Livingstone M, Fraser IS. Mechanisms of abnormal uterine bleeding. Hum Reprod. 2002;8(1):60-7.

Phillip CS, Dilley AS, Miller CH. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost. 2003;1(3):477-84.

Menorrhagia. Chapter 24 In. Padubidri VG, Daftary SN, editors. Howkins and Bourne Shaw’s Textbook of Gynaecology. 16th Edition. Elsevier; 2011:339.

Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea. Br Med J. 2006;332:1134-8.

Horne AW, Critchley HOD. Menstrual Problems: Heavy Menstrual Bleeding and Primary Dysmenorrhoea. Chapter-42 In. Edmonds DK, editor. Dewhurst's Textbook of Obstetrics and Gynecology. 8th Edition. Wiley-Blackwell Science; 2012:534-543.

Ylikorkala O. Prostaglandin Synthesis Inhibitors in Menorrhagia, Intrauterine Contraceptive Device- Induced Side Effects and Endometriosis. Pharmacol Toxicol. 1994; 75 Suppl 2:86-8.

Casablanca Y. Management of dysfunctional uterine bleeding. Obstet Gynecol Clin North Am. 2008;35(2):219-34.

National Institute for Health and Care Excellence (NICE). Clinical Guideline 44; Heavy menstrual bleeding; 2007. Available at: http://www.nice.org.uk/nicemedia/pdf/CG44FullGuideline.pdf. [accessed on 24 July 2016]

Lethaby A, Duckitt K, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2013. [cited 2017 Jan 24]. Available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000400.pub3/abstract;jsessionid=94F9FDAFF243FFBE504877A60517E86C.f02t02

Protheroe J. Modern management of menorrhagia. J Fam Plann Reprod Health Care. 2004;30(2):118-22.

Maybin JA, Critchley HO. Medical management of heavy menstrual bleeding. Women’s Health. 2016;12(1):27-34.

Hall P, Maclachlan N, Thorn N, Nudd MW, Taylor CG, Garrioch DB. Control of menorrhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid. Br J Obstet Gynaecol. 1987;94(6):554-8.

Riihiluoma P, Wuolijoki E, Pulkkinen MO. Treatment of Primary Dysmenorrhea with Diclofenac Sodium. Europ J Obstet Gynec Reprod Biol. 1981;12:189-94.

Ylikorkala O, Viinikka L. Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. Br J Obstet Gynaecol. 1983;90(1):78-83.

Cameron IT, Lumsden M, Smith SK. The Effects of Mefenamic Acid and Norethisterone on Measured Menstrual Blood Loss. Obstet Gynaecol. 1990;76(1):85-8.

Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Ame J Obstet Gynecol. 1991 Mar 1;164(3):879-83.

Pringsheim T, Davenport WJ, Dodick D. Acute Treatment and Prevention of Menstrually Related Migraine Headache: Evidence-Based Review. Neurology. 2008;70(17):1555-63.

Higham JM, O’Brien PMS, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990;97:734-9.

Hungund S, Thakkar R. Effect of pretreatment with ketorolac tromethamine on operative pain during periodontal surgery: A case-control study. J Indian Soc Periodontol. 2011;15(1):55-8.

van Eijkeren MA, Christiaens GC, Geuze HJ, Haspels AA, Sixma JJ. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. Am J Obstet Gynecol. 1992;166(5):1419-28.

Fraser IS, Pearse C, Shearman RP, Elliott PM, McIlveen J, Markham R. Efficacy of mefenamic acid in patients with a complaint of menorrhagia. Obstet Gynaecol. 1981;58(5):543-51.

Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. Br Med J. 1996;313(7057):579-82.

Coulter A, Kelland J, Peto V, Rees MC. Treating menorrhagia in primary care: an overview of drug trials and a survey of prescribing practice. Int J Tech Assess Health Care. 1995;11(3):456-71.

Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. Br J Obstet Gynaecol. 1989;96(7):840-4.

Chamberlain G, Freeman R, Price F, Kennedy A, Green D, Eve L. A comparative study of ethamsylate and mefenamic acid in dysfunctional uterine bleeding. Br J Obstet Gynaecol. 1991;98(7):707-11.

Zhang WY, Po ALW. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol. 1998;105:780-9.

Roy S. A double-blind comparison of a propionic acid derivative (ibuprofen) and a fenamate (mefenamic acid) in the treatment of dysmenorrhea. Obstet Gynecol. 1983;61(5):628-32.

Downloads

Published

2018-09-24

How to Cite

Kumar, S., Tekur, U., Singh, B., & Kumar, D. (2018). Mefenamic acid and diclofenac in the treatment of menorrhagia and dysmenorrhea in dysfunctional uterine bleeding: a randomized comparative study. International Journal of Basic & Clinical Pharmacology, 7(10), 1905–1911. https://doi.org/10.18203/2319-2003.ijbcp20183921

Issue

Section

Original Research Articles